Amgen-LabCentral Golden Ticket Competition 2023
0
Days Left
to Enter

Amgen is thrilled to accept submissions for the 2023 Amgen-LabCentral Golden Ticket Competition!

As a Platinum Sponsor of LabCentral, Amgen will award two promising start-up companies with a highly sought-after Golden Ticket to LabCentral, which:

  • Provides the winning start-ups with access to LabCentral’s laboratory space at 700 Main Street in Kendall Square (Cambridge, MA), including the benefits of LabCentral’s shared infrastructure, equipment, and services. Winners receive a $50,000 credit at LabCentral’s 700 Main Street facility, which can be used toward the recipient’s monthly invoice of lab benches, private suites, dedicated desks, private offices, per person fees, or parking.
  • Matches the winning start-ups with experienced Amgen scientists for a year of mentorship—we will provide insight and expertise based on the advice you need to further your work
  • Gives winners access to talent and expertise across Amgen’s global network

We welcome applications for innovative and groundbreaking advancements that align with Amgen’s areas of focus, including:

  • Cardiovascular and metabolic diseases, oncology, and inflammation
  • AI/ML platforms for R&D including data science / protein & generative design
  • Emerging platform technologies in the fields of discovery biology and small molecules, such as
    • Manufacturing innovation
    • Drug delivery
    • RNA Therapeutics
    • Small molecule hit discovery / novel screening methodologies / microscale and automated synthesis
    • Protein degradation and other proximity biology

Submissions are due by Monday, May 1, 2023, at 11:59 PM EDT

Once submitted, your company’s proposal will be reviewed by an internal committee of Amgen scientists, and five finalists will be selected and notified in early May. Finalists will be invited to pitch their company to an expert panel of Amgen leaders, as well as an audience including local leaders and venture capitalists at a local in-person event in late May or early June.

Questions? Contact us at GoldenTicket@amgen.com

For more ways to engage with Amgen, visit www.amgenbd.com

To apply, upload a non-confidential slide deck detailing the following:

  • Your company’s mission
  • Executive Summary (including concept and key differentiators)
  • Upcoming key milestones (including financing)
  • Commercialization/IP strategy
  • Management team/Advisors
  • Anticipated benefits of securing an Amgen–LabCentral Golden Ticket

Submissions are due by Monday, May 1, 2023, at 11:59 PM EDT

Questions? Contact us at GoldenTicket@amgen.com

For more ways to engage with Amgen, visit www.amgenbd.com

------------------------------------------------------------------------

Eligibility and Areas of interest

  • Companies must be in the life sciences and have an impact on human health.
  • Total equity funding raised must be less than $10M USD before the Golden Ticket is issued.
  • Companies must not have trailing 12-month revenues in excess of $3M USD.

Other

  • All resident companies at LabCentral, including Golden Ticket recipients, are required to have a lab presence at minimum.
  • If there is no lab space available, the value of the Golden Ticket will be extended while the company remains on the waitlist for a bench.
  • Must be financially and scientifically ready to move into LabCentral upon application for the Golden Ticket.
  • Value of the Golden Ticket award expires 13 months from the date a company is offered lab space to start.